BioSpace News Archive

New Protein, Planet and Pet Pledges, aligned to United Nations Sustainable Development Goals, aim to provide improved access to nutritious protein, reduce the company’s and customers’ footprint on the planet, and help support more healthy pets that in turn support people’s wellbeing.

Dermavant’s Pivotal Phase 3 PSOARING Data for Tapinarof Cream in Adults with Plaque Psoriasis Selected as Late-Breaking Oral Presentation at the 29 th European Academy of Dermatology and Venereology (EADV) Virtual Congress - Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - To Date, Over 2,200 Subjects Have Enrolled in 18 Clinical Trials of Tapinarof – - New Drug Application Filing Anticipated in 20

Ashvattha Therapeutics, a clinical-stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.

LEO Pharma Inc. today announced that data from across its dermatology portfolio of approved and investigational medicines will be presented at the 29th Congress of the European Academy of Dermatology and Venereology (EADV), Vienna, Oct. 29-31, 2020. EADV’s 29th Congress will be fully virtual.

Tivity Health, Inc. (NASDAQ: TVTY) will present at the 29 th Annual Credit Suisse Virtual Healthcare Conference to be held November 9-12, 2020 . Richard Ashworth , president & chief executive officer, Adam Holland , chief financial officer and Tommy Lewis , chief operating officer, will participate in a fireside chat at

Sensorion and Novasep announce the signature of an agreement for the manufacturing of adeno-associated virus vectors.

Hemogenyx Pharmaceuticals plc announces that it has extended a development agreement with a leading global pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products.

Financing will support the clinical development of Prokarium’s microbial immunotherapy for non-muscle invasive bladder cancer as well as expansion of pipeline across multiple solid tumours

Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology

Trimedic Therapeutics has submitted to Health Canada an application for the importation and sale of its COVID-19 rapid antigen test under the Interim Order pathway.